Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013
Background: Schizophrenia is a costly illness to treat, especially during a time of escalating medicine inflation costs, putting a large economic strain on patients, their families and the community. Treatment, however, can become more affordable through generic substitution. Objective: To determine...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Afrikaans |
| Published: |
AOSIS
2016-12-01
|
| Series: | Health SA Gesondheid: Journal of Interdisciplinary Health Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1025984816300242 |
| _version_ | 1818529373319331840 |
|---|---|
| author | D. Husselmann R. Joubert J.R. Burger M.S. Lubbe M. Cockeran |
| author_facet | D. Husselmann R. Joubert J.R. Burger M.S. Lubbe M. Cockeran |
| author_sort | D. Husselmann |
| collection | DOAJ |
| description | Background: Schizophrenia is a costly illness to treat, especially during a time of escalating medicine inflation costs, putting a large economic strain on patients, their families and the community. Treatment, however, can become more affordable through generic substitution.
Objective: To determine the maximum potential cost-saving through generic substitution for both originator and more expensive generic items while observing the prescribing patterns of antipsychotics.
Method: Antipsychotic medicine usage was analysed retrospectively during the study period 2008 to 2013 using data obtained from a nationally representative Pharmaceutical Benefit Management Company. The study population consisted of 4410 patients with ICD-10 codes (F20-F20.9) who had paid claims for an antipsychotic reimbursed from their prescribed minimum benefits. Active ingredients were identified using the MIMS classification system. Maximum potential cost savings were determined by substituting all originator and more expensive generic antipsychotic items with the cost of the least expensive generic antipsychotic item available.
Results: Through generic substitution, a total potential cost-saving of ZAR4 642 685.45 could be possible from 2008 to 2013. Average cost per items increased from ZAR600.53 ± ZAR435.00 (median ZAR 539.82) in 2008 to ZAR1 196.59 ± ZAR 942.16 (median ZAR 940.72) in 2013 and had a significant effect on patients' contribution, which increased with 726.94% from 2005 to 2008. Psychiatrists prescribed the majority of antipsychotics. Although generic items claimed increased by 60.31% during the study period, psychiatrists still favoured non-generic prescribing (40.63%).
Conclusions: Potential economic benefits can be generated with generic substitution. |
| first_indexed | 2024-12-11T17:06:03Z |
| format | Article |
| id | doaj.art-eba8ae146f0841e6bb7f703fa2813822 |
| institution | Directory Open Access Journal |
| issn | 1025-9848 |
| language | Afrikaans |
| last_indexed | 2024-12-11T17:06:03Z |
| publishDate | 2016-12-01 |
| publisher | AOSIS |
| record_format | Article |
| series | Health SA Gesondheid: Journal of Interdisciplinary Health Sciences |
| spelling | doaj.art-eba8ae146f0841e6bb7f703fa28138222022-12-22T00:57:41ZafrAOSISHealth SA Gesondheid: Journal of Interdisciplinary Health Sciences1025-98482016-12-0121C35636310.1016/j.hsag.2016.07.004Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013D. Husselmann0R. Joubert1J.R. Burger2M.S. Lubbe3M. Cockeran4Medicine Usage in South Africa, Faculty of Health Sciences, North-West University, Potchefstroom, South AfricaPharmacy Practice, School of Pharmacy, Faculty of Health Sciences, North-West University, Potchefstroom, South AfricaMedicine Usage in South Africa, Faculty of Health Sciences, North-West University, Potchefstroom, South AfricaMedicine Usage in South Africa, Faculty of Health Sciences, North-West University, Potchefstroom, South AfricaMedicine Usage in South Africa, Faculty of Health Sciences, North-West University, Potchefstroom, South AfricaBackground: Schizophrenia is a costly illness to treat, especially during a time of escalating medicine inflation costs, putting a large economic strain on patients, their families and the community. Treatment, however, can become more affordable through generic substitution. Objective: To determine the maximum potential cost-saving through generic substitution for both originator and more expensive generic items while observing the prescribing patterns of antipsychotics. Method: Antipsychotic medicine usage was analysed retrospectively during the study period 2008 to 2013 using data obtained from a nationally representative Pharmaceutical Benefit Management Company. The study population consisted of 4410 patients with ICD-10 codes (F20-F20.9) who had paid claims for an antipsychotic reimbursed from their prescribed minimum benefits. Active ingredients were identified using the MIMS classification system. Maximum potential cost savings were determined by substituting all originator and more expensive generic antipsychotic items with the cost of the least expensive generic antipsychotic item available. Results: Through generic substitution, a total potential cost-saving of ZAR4 642 685.45 could be possible from 2008 to 2013. Average cost per items increased from ZAR600.53 ± ZAR435.00 (median ZAR 539.82) in 2008 to ZAR1 196.59 ± ZAR 942.16 (median ZAR 940.72) in 2013 and had a significant effect on patients' contribution, which increased with 726.94% from 2005 to 2008. Psychiatrists prescribed the majority of antipsychotics. Although generic items claimed increased by 60.31% during the study period, psychiatrists still favoured non-generic prescribing (40.63%). Conclusions: Potential economic benefits can be generated with generic substitution.http://www.sciencedirect.com/science/article/pii/S1025984816300242Generic substitutionPotential cost-savingOriginatorGenericNon-genericAntipsychoticsSouth Africa |
| spellingShingle | D. Husselmann R. Joubert J.R. Burger M.S. Lubbe M. Cockeran Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013 Health SA Gesondheid: Journal of Interdisciplinary Health Sciences Generic substitution Potential cost-saving Originator Generic Non-generic Antipsychotics South Africa |
| title | Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013 |
| title_full | Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013 |
| title_fullStr | Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013 |
| title_full_unstemmed | Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013 |
| title_short | Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013 |
| title_sort | maximum potential cost savings attributable to generic substitution of antipsychotics 2008 to 2013 |
| topic | Generic substitution Potential cost-saving Originator Generic Non-generic Antipsychotics South Africa |
| url | http://www.sciencedirect.com/science/article/pii/S1025984816300242 |
| work_keys_str_mv | AT dhusselmann maximumpotentialcostsavingsattributabletogenericsubstitutionofantipsychotics2008to2013 AT rjoubert maximumpotentialcostsavingsattributabletogenericsubstitutionofantipsychotics2008to2013 AT jrburger maximumpotentialcostsavingsattributabletogenericsubstitutionofantipsychotics2008to2013 AT mslubbe maximumpotentialcostsavingsattributabletogenericsubstitutionofantipsychotics2008to2013 AT mcockeran maximumpotentialcostsavingsattributabletogenericsubstitutionofantipsychotics2008to2013 |